AbbVie(ABBV) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - The company reported full-year adjusted earnings per share of $10, exceeding initial guidance by $0.54, with total net revenues of $61.2 billion, surpassing guidance by over $2 billion [5][6] - Sales growth of 8.6% led to record net sales, exceeding previous peak revenue by more than $3 billion despite nearly $16 billion erosion from U.S. Humira [6][9] - Adjusted earnings per share for the fourth quarter were $2.71, $0.08 above guidance midpoint, with total net revenues of $16.6 billion, reflecting robust growth of 10% [32][33] Business Line Data and Key Metrics Changes - Immunology revenues reached approximately $8.6 billion, with Skyrizi sales of $5 billion (31.9% operational growth) and Rinvoq sales of nearly $2.4 billion (28.6% operational growth) [10][11] - Neuroscience full-year revenues exceeded $10.7 billion, with Vraylar and Botox Therapeutic driving significant growth [17] - Oncology revenues were nearly $1.7 billion in the quarter, with Venclexta sales of $710 million, reflecting strong demand [19] Market Data and Key Metrics Changes - Global sales for Skyrizi in IBD were approximately $6.4 billion, more than double the prior year's performance [13] - Humira delivered global sales of over $1.2 billion, down 26.1% operationally due to biosimilar competition [16] - The aesthetics segment delivered global sales of nearly $1.3 billion, with Botox Cosmetic revenues of $717 million, up 3.8% [20][21] Company Strategy and Development Direction - The company plans to deliver total sales growth of 9.5% in 2026, driven by Skyrizi and Rinvoq, with combined sales expected to exceed $31 billion [7][8] - A voluntary agreement with the U.S. government aims to enhance patient access and affordability while committing $100 billion in U.S. R&D and capital investments over the next decade [9] - The company is focused on expanding its pipeline through strategic transactions, investing over $5 billion in new business development [6][7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's strong position to deliver high single-digit revenue growth through 2029, despite headwinds from Humira erosion and Imbruvica IRA pricing [8][9] - The outlook for diverse product portfolios remains strong, with expectations for substantial sales ramp for Vyalev and continued double-digit growth from migraine products [8][9] - Management highlighted the potential for sustained long-term growth driven by innovative therapies and pipeline advancements [9][10] Other Important Information - The company anticipates free cash flow of approximately $18.5 billion in 2026, supporting a strong and growing quarterly dividend [38][39] - The adjusted operating margin is expected to expand to approximately 48.5% in 2026 [36] Q&A Session Summary Question: Details on the psychedelic therapy in development - Management highlighted the potential of the psychedelic therapy, noting its unique mechanism and observed high levels of efficacy, with further readouts expected [42][43][44] Question: Immunology franchise performance and growth expectations - Management confirmed stable new patient starts for Skyrizi in both Crohn's and UC, with high capture rates despite competition, indicating confidence in continued growth for Skyrizi and Rinvoq [51][53][55][56] Question: Update on external innovation and business development - The company has invested over $8 billion in external innovation, focusing on early-stage opportunities while remaining open to late-stage assets to enhance growth drivers [64][66] Question: Expectations for Rinvoq and Lutikizumab phase 3 data - Management expressed excitement for the upcoming studies, emphasizing the importance of efficacy in treatment failure populations and the potential for both assets to capture significant market share [68][70]